Navigation Links
Human Pheromone Sciences Announces Quarterly and Full Year Results
Date:3/31/2008

SAN JOSE, Calif., March 31, 2008 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the three months and the year ended December 31, 2007. For the three months ended December 31, 2007, net revenue was $389,000, representing a 6% decrease from revenues of $412,000 in the prior year period, and resulted in net income of $38,000 ($.01 per share) as compared with a net income of $66,000 ($.02 per share) for the same period of 2006. For the full year, net revenues of $1,291,000, were 5% higher than revenues of $1,227,000 generated in the prior year. The net loss in the current year of $16,000 ($.00 per share) was a reduction from the $111,000 loss ($.03 per share) recorded for the full year of 2006.

"In the third and fourth quarters of 2006, we had very large orders from our largest purchaser of pheromones that were not replicated in the current year quarters. As such, for the full year, revenue from pheromone sales were $207,000 (24%) lower than in 2007, while revenues attributable to licensing activities rose by $344,000 (188%) from the prior year. The growth in total revenues in the current year is attributable to the licensing activities. Lower operating expenses, coupled with the revenue growth, gave rise to the improved bottom line in the current year," a spokesperson indicated.

"These cyclical pheromone purchases are unpredictable and, as such, we developed a set of strategic imperatives to grow our licensing revenues, to formulate a program to maximize revenues from our proprietary Natural Attractions(R) brand and to complete human testing on additional novel compounds that can contribute to the expansion of our business through the scientific validation of additional technologies that will enhance the value of our Company," a spokesman noted. "While we are not pleased by the financial results for the current year fourth quarter as compared with the prior ye
'/>"/>

SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of the ... in Marshall. The Ralco Enrichment Center is an interactive experience where the public can ... lives. This unique exhibit also features a birthing center for fair goers to watch ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... In Vivo Data Show AEZS-126 as Promising Oral Compound ... 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: ... on endocrine therapy and oncology, today presented two posters ... the PI3K/ Akt pathway in human tumors. The posters ...
... the Annual General Meeting of Syngenta AG on 21 ... by the Board of Directors. Shareholders approved a dividend ... 2008, an increase of 25% over the previous year. ... to CHF 9,459,984.90 through the cancellation of 2,315,008 shares, ...
... Vantia Therapeutics, a,company developing novel small molecule drugs ... of Rachel Morten as Head of,Regulatory Affairs. , ... 24 years experience in global regulatory affairs and,product ... Most,recently an independent regulatory affairs consultant, Rachel has ...
Cached Biology Technology:AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting 2AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting 3Syngenta holds Annual General Meeting 2Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 2Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 3Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 4
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... condition involves much more than adhering to a routine ... carefully monitoring the ongoing toll this disease takes on ... tool created by Columbia University researchers and reported today ... Optics Express may soon make it easier to ...
... of island archipelagos is of considerable interest to biologists. ... biological diversity rapidly and permitting many mechanisms to be ... Such islands are often the places of new discoveries, ... Republic of Cape Verde comprises 10 inhabited islands ...
... marked the deadline for the political targets to significantly ... the 2010 goal stimulated the setting up of new ... ecosystems and their services has been incorporated in several ... meet these challenging targets requires a critical review of ...
Cached Biology News:Shedding new light on one of diabetes' most dangerous complications 2Bees that go 'Cuckoo' in others' nests 2Biodiversity conservation depends on scale: Lessons from the science-policy dialogue 2